These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
9. Effects of the catechol-O-methyltransferase inhibitor tolcapone in Parkinson's disease: correlations between concentrations of dopaminergic substances in the plasma and cerebrospinal fluid and clinical improvement. Tohgi H; Abe T; Yamazaki K; Saheki M; Takahashi S; Tsukamoto Y Neurosci Lett; 1995 Jun; 192(3):165-8. PubMed ID: 7566641 [TBL] [Abstract][Full Text] [Related]
10. Minor effect of tolcapone, a catechol-O-methyltransferase inhibitor, on extracellular dopamine levels modified by amphetamine or pargyline: a microdialysis study in anaesthetized rats. Tuomainen P; Törnwall M; Männistö PT Pharmacol Toxicol; 1996 Jun; 78(6):392-6. PubMed ID: 8829199 [TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic modeling of levodopa in patients with advanced Parkinson disease. Adamiak U; Kaldonska M; Klodowska-Duda G; Wyska E; Safranow K; Bialecka M; Gawronska-Szklarz B Clin Neuropharmacol; 2010 May; 33(3):135-41. PubMed ID: 20216409 [TBL] [Abstract][Full Text] [Related]
12. Effects of catechol-O-methyltransferase inhibitors and L-3,4-dihydroxyphenylalanine with or without carbidopa on extracellular dopamine in rat striatum. Kaakkola S; Wurtman RJ J Neurochem; 1993 Jan; 60(1):137-44. PubMed ID: 8417137 [TBL] [Abstract][Full Text] [Related]
13. Modulation of rat brain endogenous dopamine metabolism by new inhibitors of catechol O-methyltransferase. Törnwall M; Tuomainen P; Männistö PT Eur J Pharmacol; 1993 Aug; 239(1-3):39-45. PubMed ID: 8223912 [TBL] [Abstract][Full Text] [Related]
14. In vivo studies of striatal dopamine release and metabolism following administration of L-dopa. Brannan T; Knott P; Kaufmann H; Yahr M Adv Neurol; 1990; 53():75-81. PubMed ID: 2173378 [No Abstract] [Full Text] [Related]
15. Effects of tolcapone, a novel catechol-O-methyltransferase inhibitor, on striatal metabolism of L-dopa and dopamine in rats. Napolitano A; Zürcher G; Da Prada M Eur J Pharmacol; 1995 Feb; 273(3):215-21. PubMed ID: 7737328 [TBL] [Abstract][Full Text] [Related]
16. Effects of tolcapone in Parkinson's patients taking L-dihydroxyphenylalanine/carbidopa and selegiline. Davis TL; Roznoski M; Burns RS Mov Disord; 1995 May; 10(3):349-51. PubMed ID: 7651456 [TBL] [Abstract][Full Text] [Related]
17. Effect of intracerebral 6-nitronoradrenaline, an endogenous catechol-O-methyltransferase (COMT) inhibitor, on striatal dopamine metabolism in anaesthetised rats. Huotari M; Passlin M; Nordberg HL; Forsberg M; Kotisaari S; Tuomisto L; Shintani F; Tanaka KF; Reenilä I; Laitinen K; Männistö PT J Neurosci Methods; 2001 Aug; 109(1):47-52. PubMed ID: 11489299 [TBL] [Abstract][Full Text] [Related]
18. Neurochemical and psychomotor interactions of new selective COMT inhibitors with clorgyline and nomifensine in levodopa-treated rats and mice. Törnwall M; Tuomainen P; Männistö PT Arch Int Pharmacodyn Ther; 1992; 320():5-20. PubMed ID: 1300941 [TBL] [Abstract][Full Text] [Related]
19. The role of physicochemical properties of entacapone and tolcapone on their efficacy during local intrastriatal administration. Forsberg MM; Huotari M; Savolainen J; Männistö PT Eur J Pharm Sci; 2005 Apr; 24(5):503-11. PubMed ID: 15784340 [TBL] [Abstract][Full Text] [Related]
20. Coadministration of β-asarone and levodopa increases dopamine in rat brain by accelerating transformation of levodopa: a different mechanism from Madopar. Huang L; Deng M; Zhang S; Fang Y; Li L Clin Exp Pharmacol Physiol; 2014 Sep; 41(9):685-90. PubMed ID: 24910244 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]